The goal of this trial, is to assess the safety, tolerability, and pharmacokinetics of single and multiple doses of an investigational study drug in adults with symptomatic Neurogenic Orthostatic Hypotension (nOH) associated with Parkinson's disease.
Am I eligible to participate?
People 18 years or older with a clinical diagnosis of symptomatic nOH associated with Parkinson’s disease may be eligible.
Eligible patients must have persistent symptoms of nOH for 14 days prior to screening, and must not be taking anti-hypertensive medications or droxidopa.
Other inclusion and exclusion criteria may apply—we welcome you to contact our research team to learn if participating in this trial is right for you.
What does participation involve?
Subjects will receive doses during five separate occasions, approximately 7-10 days apart, with one of four single escalating doses of study drug or placebo, and undergo an orthostatic challenge test to assess the safety, tolerability, and effect on blood pressure and pharmacokinetics.
Eligible patients will also complete an nOH symptomatic assessment following the orthostatic challenge.
Participation is expected to last up to 10 weeks.
If you’re interested in enrolling, please submit this brief form, and a member of our research team will contact you.
You’re also welcome to contact the research team directly at 425.899.5385 or EvergreenResearch@evergreenhealth.com. We look forward to discussing your participation and answering your questions.